Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to$ 22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to$ 14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per ...